NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Clinical trials for NON-MUSCLE INVASIVE BLADDER NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER NEOPLASMS trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted therapy aims to keep bladder cancer from returning
Disease control Recruiting nowThis study tests a new treatment called TAR-210 (a drug placed directly into the bladder) against standard chemotherapy for people with a high-risk type of bladder cancer that has certain genetic changes (FGFR alterations). All participants have already received a standard treatm…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
New bladder cancer drug could delay recurrence without chemo
Disease control Recruiting nowThis study tests a new treatment called TAR-210, which delivers a targeted drug directly into the bladder, against standard chemotherapy for people with intermediate-risk non-muscle invasive bladder cancer that has certain genetic changes (FGFR alterations). The goal is to see if…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 03, 2026 12:02 UTC
-
New bladder cancer treatment tracked in Real-World study
Disease control Recruiting nowThis study looks at how well TAR-200 works for people with early-stage bladder cancer (NMIBC) in real-world settings. Researchers will measure how long it takes for the cancer to come back or get worse after starting TAR-200. About 150 participants who have already started TAR-20…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 01, 2026 18:08 UTC
-
Bladder cancer drug delivered straight to the source in new trial
Disease control Recruiting nowThis study tests a special device (TAR-210) that releases the drug erdafitinib directly into the bladder for people with non-muscle-invasive or muscle-invasive bladder cancer. The goal is to find the best dose and see if it can shrink or control tumors. About 235 adults whose can…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 01, 2026 18:03 UTC
-
New vaccine-like therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 01, 2026 17:54 UTC
-
New injection targets bladder tumors in early trial
Disease control Recruiting nowThis early-stage study is testing whether a new drug, belzupacap sarotalocan, can be safely injected directly into bladder tumors. The trial involves about 55 people with non-muscle-invasive bladder cancer. Researchers will monitor side effects and check if the treatment helps sh…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated May 28, 2026 12:03 UTC